20170425 PR Q1-2017
Month: April 2017
Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer
20170425 BMS-Clinical Collaboration Release Transgene-FINAL
SillaJen and Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer
20170424 PR PHOCUS FPI EU – EN
Kempen 10th Life Sciences Conference: April 19, 2017 – Amsterdam, Netherlands
Marie Landel and Maya Said Nominated to be Independent Members of Transgene’s Board of Directors
20170419 TG Appointments Board EN
Transgene and Institut Bergonié Start the Phase 2 Part of the METROmaJX Trial
20170412 PR Metro-JX Ph2 EN
Transgene Announces Upcoming Investor Meetings and R&D Day
20170410 PR Next investor events
Local and Abscopal Effects in Oncolytic Virotherapy are boosted by Immune Checkpoint Blockade, Immunogenic Chemotherapy, or IFNAR blockade
Laetitia Fend, et al. AACR, American Association for cancer Research, April 2017 Download the poster here Poster Presentation
In situ Biomarker analysis in cancer Immunotherapy: development of quantitative multiplex IHC
Sandrine Cochin, et al. CLARA, Forum de la recherche en cancérologie, April 2017 Download the poster here Poster Presentation